Under the leadership of Secretary Kennedy and FDA Commissioner Martin A. Makary, FDA plans to roll out several key actions over the coming months, including:

• A modernized, evidence-based prioritization scheme for reviewing existing chemicals. A draft will be released for public comment soon.
• A final, systematic post-market review process shaped by stakeholder input.
• An updated list of chemicals under review, including BHT, BHA, and ADA. FDA will also take steps to expedite its review of chemicals currently under review like phthalates, propylparaben, and titanium dioxide. FDA will continue to share information about the status of this work on its public website as part the agency’s push for greater transparency.

Until now, FDA has conducted post-market reviews on a case-by-case basis, often in response to citizen petitions or new scientific evidence. “This new framework will be proactive, science-based, and built for long-term impact. Americans are demanding more transparency and accountability around food safety and the FDA is doing just that,” HHS said in a statement.

“We are prioritizing our resources and leveraging gold standard science to create, for the first time, a systematic post-market review program that consumers can trust and rely on,” said FDA Commissioner Makary. “Only by improving the safety and transparency of the food supply and ensuring consumers can make healthful food choices will we overcome the long-standing trajectory of chronic diseases.”